Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide

University of Southern California

Status: Withdrawn

Conditions: Small Cell Lung Cancer

Treatments: Other: laboratory biomarker analysis; Other: cytology specimen collection procedure

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT02250404

2O-13-1 (Other Identifier)

HS-14-00382

P30CA014089 (U.S. NIH Grant/Contract)

NCI-2014-01910 (Registry Identifier)

UL1TR000130 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This pilot research trial studies molecular signatures of the return of cancer after a period of improvement (relapse) in tissue samples from patients with small cell lung cancer who are receiving or planning to receive cisplatin and etoposide. Studying samples of tissue from patients with small cell lung cancer in the laboratory may help doctors learn more about the changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer relapse.

Full description

PRIMARY OBJECTIVES:

I. To collect and analyze small cell lung cancer (SCLC) tumor DNA and ribonucleic acid (RNA) from 3 human patients before and after relapse to identify the molecular signatures of relapse.

OUTLINE:

Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Any patient seen at Norris or County with histologically confirmed SCLC, with tissue in the Norris Cancer Center Tumor Repository
• Patients must be undergoing or about to start first line treatment with cisplatin and etoposide
• Patients may not have a second malignancy

Trial design

0 participants in 1 patient group

Ancillary-Correlative (molecular profile)

Description:

Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.

Treatment:

Other: cytology specimen collection procedure

Other: laboratory biomarker analysis